Analyst Profile

Followed by 235 followers
.
Jessica Fye

Jessica Fye

J.P. Morgan
Wall Street Analyst
#755 out of 8,143 Wall Street Analysts
#1,577 out of 24,358 experts

Success Rate

55%
104 out of 189 transactions made a profit

Average Return

+10.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Jessica Fye's trades since 2010 and holding each position for 1 Year would result in 55.03% of your transactions generating a profit, with an average return of 10.2% per rating.

Stock Rating Distribution

359Ratings
53.48% Buy
39.83% Hold
6.69% Sell
Distribution of Jessica Fye's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Nektar Therapeutics
(NKTR)
Rating:Buy
Date:Mar 21, 2017 - Mar 21, 2018
Return:+389.70%
The most profitable rating made by Jessica Fye

Jessica Fye's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
~FRX
Forest Labs
May 18, 2010
Sell
Reiterated
1Ratings
0%
-27.00%
VVUSQ
Vivus
May 04, 2016
Hold
Reiterated
1Ratings
0.00%
OREXQ
Orexigen
Aug 04, 2016
Hold
Reiterated
5Ratings
0%
-74.20%
AEGR
Aegerion
Nov 29, 2016
Hold
Reiterated
2Ratings
0.00%
ALDR
Alder Biopharmaceuticals
Feb 24, 2017
Buy
Reiterated
2Ratings
0%
-49.85%
MLNTQ
Melinta Therapeutics
Feb 28, 2017
Hold
Reiterated
5Ratings
0%
-63.85%
AAAP
Advanced Accelerator Applications
Nov 20, 2017
Hold
Downgraded
1Ratings
0.00%
Enanta Pharmaceuticals
Feb 08, 2018
Hold
Downgraded
$95.00
(116.94% Upside)
4Ratings
100%
+65.65%
Chimerix
Feb 14, 2018
Sell
Downgraded
5Ratings
100%
+60.00%
Novavax
Mar 19, 2018
Sell
Downgraded
3Ratings
100%
+73.50%
List of latest recommendations made by Jessica Fye. Click to expand and see Jessica Fye's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >